Chiara Pastrello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chiara Pastrello has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
- Igor Jurisica
University of Toronto 1 Faculty of Dentistry Toronto, Canada
18 shared publications - Max Kotlyar
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, and Data Science Discovery Centre for Chronic Diseases, Krembil Research Institute, Toronto, ON M5T 0S8, Canada
6 shared publications - Mohit Kapoor
Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada; Department of Surgery and Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada
6 shared publications Igor Jurisica
Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics and computer Science, and Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
5 shared publications- Ana Konvalinka
Toronto General Hospital Research Institute, University Health Network, Canada (S.F., K.P.M., A. Konvalinka)
4 shared publications - Anjalia Shrivastava
European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK
4 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Altered Complement and Tubular Mitochondrial Proteins Are Linked to Graft Loss in DSA+ Antibody–Mediated Rejection
Key Points: DSA + kidney grafts with antibody-mediated rejection had higher glomerular and tubulointerstitial complement protein levels than those with donor-specific antibodies but no rejection. DSA + patients without rejection lacked accommodation but showed preserved podocyte and tubular protein expression compared with antibody-mediated rejection. Elevated complement and decreased mitochondrial proteins were associated with death-censored allograft loss in DSA + patients with antibody-mediated rejection. Background: Antibody-mediated rejection (AMR) is the main driver of late kidney allograft loss. Anti-HLA donor-specific antibodies (DSAs) are strongly associated with AMR. However, 30%–60% of DSA + patients do not develop AMR, raising the possibility of local tissue adaptations to DSAs. Methods: We performed unbiased proteomic analysis on glomeruli and tubulointerstitium isolated using laser-capture microdissection from the kidney biopsies of 116 DSA + kidney transplant recipients with Banff-classified active AMR, chronic active AMR, mixed AMR, or no rejection. The Significant Latent factor Interaction Discovery and Exploration (SLIDE) machine learning algorithm was used to identify latent factors linked to graft loss among patients with AMR. Results: We quantified 1917 glomerular and 2758 tubulointerstitial proteins by mass spectrometry, with 127 glomerular and 389 tubulointerstitial proteins significantly differentially expressed between all 4 patient groups (one-way ANOVA P < 0.05, Tukey false discovery rate + biopsies without rejection were characterized by preservation of podocyte and tubular proteins in glomeruli and tubulointerstitium, respectively, but did not show conventional markers of accommodation. SLIDE identified 3 latent factors from the glomerular proteome and 4 from the tubulointerstitial proteome that significantly distinguished AMR patients with and without graft loss, correlated significantly with allograft injury, and improved prediction of graft loss beyond standard clinical variables in a multivariable risk model. Top proteins within the glomerular SLIDE model included complement components, while top proteins for the tubulointerstitial SLIDE model included tubular and mitochondrial proteins. Conclusions: AMR and graft loss after kidney transplantation were defined by compartment-specific disruptions in complement and mitochondrial proteins.
- 13 August 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
Open AccessAltered Complement and Tubular Mitochondrial Proteins Are Linked to Graft Loss in DSA+ Antibody–Mediated Rejection
Key Points: DSA + kidney grafts with antibody-mediated rejection had higher glomerular and tubulointerstitial complement protein levels than those with donor-specific antibodies but no rejection. DSA + patients without rejection lacked accommodation but showed preserved podocyte and tubular protein expression compared with antibody-mediated rejection. Elevated complement and decreased mitochondrial proteins were associated with death-censored allograft loss in DSA + patients with antibody-mediated rejection. Background: Antibody-mediated rejection (AMR) is the main driver of late kidney allograft loss. Anti-HLA donor-specific antibodies (DSAs) are strongly associated with AMR. However, 30%–60% of DSA + patients do not develop AMR, raising the possibility of local tissue adaptations to DSAs. Methods: We performed unbiased proteomic analysis on glomeruli and tubulointerstitium isolated using laser-capture microdissection from the kidney biopsies of 116 DSA + kidney transplant recipients with Banff-classified active AMR, chronic active AMR, mixed AMR, or no rejection. The Significant Latent factor Interaction Discovery and Exploration (SLIDE) machine learning algorithm was used to identify latent factors linked to graft loss among patients with AMR. Results: We quantified 1917 glomerular and 2758 tubulointerstitial proteins by mass spectrometry, with 127 glomerular and 389 tubulointerstitial proteins significantly differentially expressed between all 4 patient groups (one-way ANOVA P < 0.05, Tukey false discovery rate + biopsies without rejection were characterized by preservation of podocyte and tubular proteins in glomeruli and tubulointerstitium, respectively, but did not show conventional markers of accommodation. SLIDE identified 3 latent factors from the glomerular proteome and 4 from the tubulointerstitial proteome that significantly distinguished AMR patients with and without graft loss, correlated significantly with allograft injury, and improved prediction of graft loss beyond standard clinical variables in a multivariable risk model. Top proteins within the glomerular SLIDE model included complement components, while top proteins for the tubulointerstitial SLIDE model included tubular and mitochondrial proteins. Conclusions: AMR and graft loss after kidney transplantation were defined by compartment-specific disruptions in complement and mitochondrial proteins.
- Open Access
- 22 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (24)
Identification of Ephrin type-B receptor 4 as a critical mediator of tissue fibrosis
Pulmonary fibrosis (PF) is a pathology associated with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). Fibrosis promotes continual secretion of extracellular matrix (ECM), producing nonfunctional scar tissue and causing organ failure. This study investigated the tyrosine kinase receptor Ephrin type-B receptor 4 (EphB4) as a mediator of PF. To this end, we generated mice with conditional Col1a2- driven deletion of Ephb4 and used a preclinical mouse model of PF, total and single nuclei RNA (snRNA) sequencing, NanoString, previously published single-cell data, computational analysis, and functional assays of mouse and human healthy control and IPF lung fibroblasts. Col1a2 -Cre ERT –driven Ephb4 deletion, or EphB4 inhibition via NVP-BHG712, markedly protected against bleomycin-induced PF. Total RNA-Seq of fibroblasts isolated from Ephb4 -deficient fibrotic mouse lungs exhibited reduced expression of ECM, ER Cargo, and protein trafficking–related genes. NVP-BHG712 reduced expression of these identified genes in mouse lung fibroblasts under fibrotic conditions in vitro. snRNA-Seq of mouse lungs treated with NVP-BHG712 identified transcriptomic changes of ECM genes in specific fibroblast subpopulations. RNA-Seq, computational, and functional assays using mouse and human IPF fibroblasts identified elastin as a key mediator involved in EphB4 signaling. Combined, our data show that EphB4 is a crucial mediator of PF.
- 22 December 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (24)
Open AccessIdentification of Ephrin type-B receptor 4 as a critical mediator of tissue fibrosis
Pulmonary fibrosis (PF) is a pathology associated with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF). Fibrosis promotes continual secretion of extracellular matrix (ECM), producing nonfunctional scar tissue and causing organ failure. This study investigated the tyrosine kinase receptor Ephrin type-B receptor 4 (EphB4) as a mediator of PF. To this end, we generated mice with conditional Col1a2- driven deletion of Ephb4 and used a preclinical mouse model of PF, total and single nuclei RNA (snRNA) sequencing, NanoString, previously published single-cell data, computational analysis, and functional assays of mouse and human healthy control and IPF lung fibroblasts. Col1a2 -Cre ERT –driven Ephb4 deletion, or EphB4 inhibition via NVP-BHG712, markedly protected against bleomycin-induced PF. Total RNA-Seq of fibroblasts isolated from Ephb4 -deficient fibrotic mouse lungs exhibited reduced expression of ECM, ER Cargo, and protein trafficking–related genes. NVP-BHG712 reduced expression of these identified genes in mouse lung fibroblasts under fibrotic conditions in vitro. snRNA-Seq of mouse lungs treated with NVP-BHG712 identified transcriptomic changes of ECM genes in specific fibroblast subpopulations. RNA-Seq, computational, and functional assays using mouse and human IPF fibroblasts identified elastin as a key mediator involved in EphB4 signaling. Combined, our data show that EphB4 is a crucial mediator of PF.
- Open Access
- 26 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D593-D600
IID 2025: Physical protein interaction data with detection types, co-purified protein sets, molecular docking, and immune cell networks
Biomedical research benefits from the rapid growth and diversity of experimentally detected protein–protein interactions (PPIs) by gaining important biological insights. However, increasingly dense PPI networks can be challenging to interpret and apply. The 2025 update of the Integrated Interactions Database (IID) enhances accessibility and utility through several new features. We identify and incorporate network structural components from co-purified protein sets, as well as curated and predicted complexes, enabling users to explore network organization beyond binary interactions. Functional, pathway, and disease associations of these components can be analyzed, enabling interactions to be grouped into higher-order structures with known or provisional biological roles. Users can now filter interactions by five detection types: pairwise, co-purification, colocalization, proximity, and other evidence. To extend the value and information of predicted interactions, we include interaction interface predictions for 53 647 PPIs, generated using the MEGADOCK docking algorithm, adding molecular detail for structural biology and variant impact studies. Finally, we map PPIs to 15 immune cell types and 12 additional normal tissues, offering tissue-specific views of interaction networks increasingly relevant in disease and immunology research. IID 2025 now includes over 1 million experimentally detected human PPIs, representing an 83% increase from the previous release, alongside expanded non-human networks. The portal remains publicly available at https://ophid.utoronto.ca/iid.
- 26 November 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D593-D600
Open AccessIID 2025: Physical protein interaction data with detection types, co-purified protein sets, molecular docking, and immune cell networks
Biomedical research benefits from the rapid growth and diversity of experimentally detected protein–protein interactions (PPIs) by gaining important biological insights. However, increasingly dense PPI networks can be challenging to interpret and apply. The 2025 update of the Integrated Interactions Database (IID) enhances accessibility and utility through several new features. We identify and incorporate network structural components from co-purified protein sets, as well as curated and predicted complexes, enabling users to explore network organization beyond binary interactions. Functional, pathway, and disease associations of these components can be analyzed, enabling interactions to be grouped into higher-order structures with known or provisional biological roles. Users can now filter interactions by five detection types: pairwise, co-purification, colocalization, proximity, and other evidence. To extend the value and information of predicted interactions, we include interaction interface predictions for 53 647 PPIs, generated using the MEGADOCK docking algorithm, adding molecular detail for structural biology and variant impact studies. Finally, we map PPIs to 15 immune cell types and 12 additional normal tissues, offering tissue-specific views of interaction networks increasingly relevant in disease and immunology research. IID 2025 now includes over 1 million experimentally detected human PPIs, representing an 83% increase from the previous release, alongside expanded non-human networks. The portal remains publicly available at https://ophid.utoronto.ca/iid.
- Open Access
- 24 December 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (3)
TRPC1 links calcium signaling to cellular senescence in the protection against posttraumatic osteoarthritis
Transient receptor potential channel 1 (TRPC1) is a widely expressed mechanosensitive ion channel located within the endoplasmic reticulum membrane, crucial for refilling depleted internal calcium stores during activation of calcium-dependent signaling pathways. Here, we have demonstrated that TRPC1 activity is protective within cartilage homeostasis in the prevention of cellular senescence–associated cartilage breakdown during mechanical and inflammatory challenge. We revealed that TRPC1 loss is associated with early stages of osteoarthritis (OA) and plays a nonredundant role in calcium signaling in chondrocytes. Trpc1 –/– mice subjected to destabilization of the medial meniscus–induced OA developed a more severe OA phenotype than WT controls. During early OA development, Trpc1 –/– mice displayed an increased chondrocyte survival rate; however, remaining cells displayed features of senescence including p16 INK4a expression and decreased Sox9. RNA-Seq identified differentially expressed genes related to cell number, apoptosis, and extracellular matrix organization. Trpc1 –/– chondrocytes exhibited accelerated dedifferentiation, while demonstrating an increased susceptibility to cellular senescence. Targeting the mechanism of TRPC1 activation may be a promising therapeutic strategy in OA prevention.
- 24 December 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (3)
Open AccessTRPC1 links calcium signaling to cellular senescence in the protection against posttraumatic osteoarthritis
Transient receptor potential channel 1 (TRPC1) is a widely expressed mechanosensitive ion channel located within the endoplasmic reticulum membrane, crucial for refilling depleted internal calcium stores during activation of calcium-dependent signaling pathways. Here, we have demonstrated that TRPC1 activity is protective within cartilage homeostasis in the prevention of cellular senescence–associated cartilage breakdown during mechanical and inflammatory challenge. We revealed that TRPC1 loss is associated with early stages of osteoarthritis (OA) and plays a nonredundant role in calcium signaling in chondrocytes. Trpc1 –/– mice subjected to destabilization of the medial meniscus–induced OA developed a more severe OA phenotype than WT controls. During early OA development, Trpc1 –/– mice displayed an increased chondrocyte survival rate; however, remaining cells displayed features of senescence including p16 INK4a expression and decreased Sox9. RNA-Seq identified differentially expressed genes related to cell number, apoptosis, and extracellular matrix organization. Trpc1 –/– chondrocytes exhibited accelerated dedifferentiation, while demonstrating an increased susceptibility to cellular senescence. Targeting the mechanism of TRPC1 activation may be a promising therapeutic strategy in OA prevention.
- Open Access
- 4 July 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (9) , 1113-1125
Early microRNA and metabolite changes after anterior cruciate ligament reconstruction surgery
- 4 July 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (9) , 1113-1125
Open AccessEarly microRNA and metabolite changes after anterior cruciate ligament reconstruction surgery
- Open Access
- 23 May 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (W1) , W481-W488
Drugst.One — a plug-and-play solution for online systems medicine and network-based drug repurposing
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.
- 23 May 2024
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (W1) , W481-W488
Open AccessDrugst.One — a plug-and-play solution for online systems medicine and network-based drug repurposing
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.
- 28 February 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (7) , 858-868
Evolution and advancements in genomics and epigenomics in OA research: How far we have come
- 28 February 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (7) , 858-868
Evolution and advancements in genomics and epigenomics in OA research: How far we have come
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D663-D671
PathDIP 5: improving coverage and making enrichment analysis more biologically meaningful
Pathway Data Integration Portal (PathDIP) is an integrated pathway database that was developed to increase functional gene annotation coverage and reduce bias in pathway enrichment analysis. PathDIP 5 provides multiple improvements to enable more interpretable analysis: users can perform enrichment analysis using all sources, separate sources or by combining specific pathway subsets; they can select the types of sources to use or the types of pathways for the analysis, reducing the number of resulting generic pathways or pathways not related to users’ research question; users can use API. All pathways have been mapped to seven representative types. The results of pathway enrichment can be summarized through knowledge-based pathway consolidation. All curated pathways were mapped to 53 pathway ontology-based categories. In addition to genes, pathDIP 5 now includes metabolites. We updated existing databases, included two new sources, PathBank and MetabolicAtlas, and removed outdated databases. We enable users to analyse their results using Drugst.One, where a drug-gene network is created using only the user's genes in a specific pathway. Interpreting the results of any analysis is now improved by multiple charts on all the results pages. PathDIP 5 is freely available at https://ophid.utoronto.ca/pathDIP.
- 22 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D663-D671
Open AccessPathDIP 5: improving coverage and making enrichment analysis more biologically meaningful
Pathway Data Integration Portal (PathDIP) is an integrated pathway database that was developed to increase functional gene annotation coverage and reduce bias in pathway enrichment analysis. PathDIP 5 provides multiple improvements to enable more interpretable analysis: users can perform enrichment analysis using all sources, separate sources or by combining specific pathway subsets; they can select the types of sources to use or the types of pathways for the analysis, reducing the number of resulting generic pathways or pathways not related to users’ research question; users can use API. All pathways have been mapped to seven representative types. The results of pathway enrichment can be summarized through knowledge-based pathway consolidation. All curated pathways were mapped to 53 pathway ontology-based categories. In addition to genes, pathDIP 5 now includes metabolites. We updated existing databases, included two new sources, PathBank and MetabolicAtlas, and removed outdated databases. We enable users to analyse their results using Drugst.One, where a drug-gene network is created using only the user's genes in a specific pathway. Interpreting the results of any analysis is now improved by multiple charts on all the results pages. PathDIP 5 is freely available at https://ophid.utoronto.ca/pathDIP.
- Open Access
- 1 August 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (8)
USNAP: fast unique dense region detection and its application to lung cancer
Many real-world problems can be modeled as annotated graphs. Scalable graph algorithms that extract actionable information from such data are in demand since these graphs are large, varying in topology, and have diverse node/edge annotations. When these graphs change over time they create dynamic graphs, and open the possibility to find patterns across different time points. In this article, we introduce a scalable algorithm that finds unique dense regions across time points in dynamic graphs. Such algorithms have applications in many different areas, including the biological, financial, and social domains. There are three important contributions to this manuscript. First, we designed a scalable algorithm, USNAP, to effectively identify dense subgraphs that are unique to a time stamp given a dynamic graph. Importantly, USNAP provides a lower bound of the density measure in each step of the greedy algorithm. Second, insights and understanding obtained from validating USNAP on real data show its effectiveness. While USNAP is domain independent, we applied it to four non-small cell lung cancer gene expression datasets. Stages in non-small cell lung cancer were modeled as dynamic graphs, and input to USNAP. Pathway enrichment analyses and comprehensive interpretations from literature show that USNAP identified biologically relevant mechanisms for different stages of cancer progression. Third, USNAP is scalable, and has a time complexity of , where m is the number of edges, and n is the number of vertices in the dynamic graph; is the number of edges, and is the number of vertices in the collapsed graph. The code of USNAP is available at https://www.cs.utoronto.ca/~juris/data/USNAP22.- 1 August 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (8)
Open AccessUSNAP: fast unique dense region detection and its application to lung cancer
Many real-world problems can be modeled as annotated graphs. Scalable graph algorithms that extract actionable information from such data are in demand since these graphs are large, varying in topology, and have diverse node/edge annotations. When these graphs change over time they create dynamic graphs, and open the possibility to find patterns across different time points. In this article, we introduce a scalable algorithm that finds unique dense regions across time points in dynamic graphs. Such algorithms have applications in many different areas, including the biological, financial, and social domains. There are three important contributions to this manuscript. First, we designed a scalable algorithm, USNAP, to effectively identify dense subgraphs that are unique to a time stamp given a dynamic graph. Importantly, USNAP provides a lower bound of the density measure in each step of the greedy algorithm. Second, insights and understanding obtained from validating USNAP on real data show its effectiveness. While USNAP is domain independent, we applied it to four non-small cell lung cancer gene expression datasets. Stages in non-small cell lung cancer were modeled as dynamic graphs, and input to USNAP. Pathway enrichment analyses and comprehensive interpretations from literature show that USNAP identified biologically relevant mechanisms for different stages of cancer progression. Third, USNAP is scalable, and has a time complexity of , where m is the number of edges, and n is the number of vertices in the dynamic graph; is the number of edges, and is the number of vertices in the collapsed graph. The code of USNAP is available at https://www.cs.utoronto.ca/~juris/data/USNAP22. - Open Access
- 1 December 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D217-D225
MirDIP 5.2: tissue context annotation and novel microRNA curation
MirDIP is a well-established database that aggregates microRNA-gene human interactions from multiple databases to increase coverage, reduce bias, and improve usability by providing an integrated score proportional to the probability of the interaction occurring. In version 5.2, we removed eight outdated resources, added a new resource (miRNATIP), and ran five prediction algorithms for miRBase and mirGeneDB. In total, mirDIP 5.2 includes 46 364 047 predictions for 27 936 genes and 2734 microRNAs, making it the first database to provide interactions using data from mirGeneDB. Moreover, we curated and integrated 32 497 novel microRNAs from 14 publications to accelerate the use of these novel data. In this release, we also extend the content and functionality of mirDIP by associating contexts with microRNAs, genes, and microRNA–gene interactions. We collected and processed microRNA and gene expression data from 20 resources and acquired information on 330 tissue and disease contexts for 2657 microRNAs, 27 576 genes and 123 651 910 gene–microRNA–tissue interactions. Finally, we improved the usability of mirDIP by enabling the user to search the database using precursor IDs, and we integrated miRAnno, a network-based tool for identifying pathways linked to specific microRNAs. We also provide a mirDIP API to facilitate access to its integrated predictions. Updated mirDIP is available at https://ophid.utoronto.ca/mirDIP.
- 1 December 2022
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 51 (D1) , D217-D225
Open AccessMirDIP 5.2: tissue context annotation and novel microRNA curation
MirDIP is a well-established database that aggregates microRNA-gene human interactions from multiple databases to increase coverage, reduce bias, and improve usability by providing an integrated score proportional to the probability of the interaction occurring. In version 5.2, we removed eight outdated resources, added a new resource (miRNATIP), and ran five prediction algorithms for miRBase and mirGeneDB. In total, mirDIP 5.2 includes 46 364 047 predictions for 27 936 genes and 2734 microRNAs, making it the first database to provide interactions using data from mirGeneDB. Moreover, we curated and integrated 32 497 novel microRNAs from 14 publications to accelerate the use of these novel data. In this release, we also extend the content and functionality of mirDIP by associating contexts with microRNAs, genes, and microRNA–gene interactions. We collected and processed microRNA and gene expression data from 20 resources and acquired information on 330 tissue and disease contexts for 2657 microRNAs, 27 576 genes and 123 651 910 gene–microRNA–tissue interactions. Finally, we improved the usability of mirDIP by enabling the user to search the database using precursor IDs, and we integrated miRAnno, a network-based tool for identifying pathways linked to specific microRNAs. We also provide a mirDIP API to facilitate access to its integrated predictions. Updated mirDIP is available at https://ophid.utoronto.ca/mirDIP.